Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies

Posted:
7
November 2012

Cardiac Safety: Key issues and best practice for Thorough QT Studiesand Intensive Phase I QT Studies~ A specialist workshop sponsored by Richmond Pharmacology ~

As collaborating sponsors of the joint AMIFE IFAPP 16th International Conference on Pharmaceutical Medicine � ICPM 2012, Richmond Pharmacology welcomes attendees to join its specialist workshop on Day 2, 15 Nov exploring �Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies�.Co-chaired by the internationally acclaimed experts Beno�t Tyl, Georg Ferber and Jorg Taubel, the workshop will look at the biological background to the ICH E14 guidance. They will present the rationale of the thorough QT study and discuss the key elements of a state of the art design and analysis of such a study. The second half of the workshop will address the placement of the TQT study in clinical development and give an update on current CSRC discussions and on conditions under which regulators may be likely to waive a TQT study at present and in future.Attendees are encouraged to submit questions or current problems they may wish the panel to address during the roundtable discussions in advance to:info@richmondpharmacology.comView ICPM 2012 Scientific ProgramRegister for this conference

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more